TP53 and breast neoplasm: Recent findings (Bertheau et al, 2007) indicate that non-inflammatory breast tumours containing mutant TP53—in particular, basal-cell-like tumours—are very sensitive to dose-dense epirubicin and cyclophosphamide chemotherapy.